We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

71 hedge funds and large institutions have $776M invested in Beam Therapeutics in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

59% more capital invested

Capital invested by funds: $489M → $776M (+$287M)

18% more funds holding

Funds holding: 60 → 71 (+11)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.87% less ownership

Funds ownership: 54.68% → 53.81% (-0.87%)

Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.46%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
19
Increased
25
Reduced
10
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$23.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.19M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.99M
4
Millennium Management
Millennium Management
New York
+$2.71M
5
BlackRock
BlackRock
New York
+$1.52M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$8.87M
2
Franklin Resources
Franklin Resources
California
-$5.41M
3
SFM
Sphera Funds Management
Israel
-$4.76M
4
FCM
Farallon Capital Management
California
-$3.06M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
ZP
76
Zimmer Partners
New York
– -$225K -12,500 Closed
SO
77
STRS Ohio
Ohio
– -$55K -3,100 Closed
NIT
78
NumerixS Investment Technologies
British Columbia, Canada
– -$36K -2,000 Closed
1 2 3
4

BEAM Hedge Fund Activity: Q2 2020 in Review

71 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2020, worth a combined $776M — up 59% from $489M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new BEAM positions and 7 closed out — a net gain of 12 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $23.1M. The largest seller was Victory Capital Management, cutting an estimated $8.87M.

  • 71 institutional investors held Beam Therapeutics (BEAM) as of Q2 2020, up from 60 in Q1 2020.
  • Funds reported $776M of Beam Therapeutics stock for Q2 2020, up 59% quarter-over-quarter.
  • 19 funds opened new Beam Therapeutics positions in Q2 2020 and 7 closed out, a net change of +12 holders.
  • The largest Beam Therapeutics buyer in Q2 2020 was Vanguard Group, an estimated $23.1M added.
  • The largest Beam Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $8.87M sold.

Based on aggregated 13F filings for Q2 2020.